|
| 37335291 | Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. | Oncotarget | 2023 |
| 35852795 | Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. | Clin Cancer Res | 2022 |
| 35610507 | Targeting aberrant replication and DNA repair events for treating breast cancers. | Commun Biol | 2022 |
| 34910551 | A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. | Sci Transl Med | 2021 |
| 33235994 | Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. | Neurooncol Adv | 2020 |
| 30993905 | Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. | Cancer Med | 2019 |
| 31477168 | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). | Breast Cancer Res | 2019 |
| 30861105 | A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. | Int J Cancer | 2019 |
| 29783757 | A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier. | Pharmaceutics | 2018 |
| 28988377 | Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. | J Neurooncol | 2018 |
| 29941486 | Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. | Clin Cancer Res | 2018 |
| 29485888 | Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts. | Molecular Pharmaceutics | 2018 |
| 29301832 | Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. | Clin Cancer Res | 2018 |
| 29608984 | Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. | Cancer Lett | 2018 |
| 29475723 | Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. | Lancet Oncol | 2018 |
| 29074604 | Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. | Clin Cancer Res | 2018 |
| 27542768 | Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. | Clinical Cancer Research | 2017 |
| 28220479 | A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. | Br J Haematol | 2017 |
| 28112516 | Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJ. | Journal of Natural Products | 2017 |
| 27026681 | Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. | Cancer Prev Res (Phila) | 2016 |
| 26341136 | Fungal metabolite ophiobolin A as a promising anti-glioma agent: In vivo evaluation, structure-activity relationship and unique pyrrolylation of primary amines. | Bioorganic and Medicinal Chemistry Letters | 2015 |
| 25934816 | Toward precision medicine in glioblastoma: the promise and the challenges. | Neuro Oncol | 2015 |
| 23525756 | A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2014 |
| 25395315 | Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. | Breast Cancer Res Treat | 2014 |
| 24470557 | Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. | Neuro Oncol | 2014 |
| 21739168 | Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. | J Neurooncol | 2012 |
| 22588883 | Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. | Cancer Discov | 2012 |
| 22923449 | Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. | Clin Cancer Res | 2012 |
| 23099651 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. | Neuro Oncol | 2012 |
| 21813511 | Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? | Neuro Oncol | 2011 |
| 21377994 | A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. | Neuro Oncol | 2011 |
| 20150371 | A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. | Neuro Oncol | 2010 |
| 20150372 | A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. | Neuro Oncol | 2010 |
| 18795290 | Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. | Cancer Chemotherapy and Pharmacology | 2009 |
| 20009104 | EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. | Sci Signal | 2009 |
| 18838439 | Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. | Oncologist | 2008 |
| 17610262 | A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. | Pediatric Blood and Cancer | 2008 |
| 17694310 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. | Cancer Chemother Pharmacol | 2008 |
| 18559968 | Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. | Neuro Oncol | 2008 |
| 18082778 | Does intraosseous equal intravenous? A pharmacokinetic study. | American Journal of Emergency Medicine | 2008 |
| 18356283 | Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. | Neuro Oncol | 2008 |
| 18094423 | Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. | Clin Cancer Res | 2007 |
| 18056194 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. | Clin Cancer Res | 2007 |
| 16685529 | Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. | Cancer Chemotherapy and Pharmacology | 2007 |
| 16877733 | Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. | J Clin Oncol | 2006 |
| 16317728 | Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. | Pediatric Blood and Cancer | 2006 |
| 16317586 | Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. | Breast Cancer Res Treat | 2006 |
| 16622259 | Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. | Journal of Clinical Oncology | 2006 |
| 16533878 | A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. | Neuro Oncol | 2006 |
| 16778106 | Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. | Clinical Cancer Research | 2006 |